GARTH MATTHEW E
GARTH MATTHEW E's purchase track record
GARTH MATTHEW E has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/7/2022 | MTX | $6K | +9.6% | -8.3% | -7.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
ScottsMiracle-Gro Appoints CIO Amid Mixed Analyst Views. ScottsMiracle-Gro has named a new Chief Information Officer to support its technology transformation and growth strategy. While Wells Fargo maintained an overweight rating, it lowered its price target to $60, reflecting cautious sentiment. Other analysts remain more optimistic, with the average target price sitting at $74.17. The stock is currently trading near its support level, indicating a period of consolidation following recent volatility.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
MTX Sets Q3 2026 Earnings Call for October 30. Minerals Technologies has scheduled its third-quarter 2026 conference call for October 30, 2026. This upcoming event will provide investors with the company's latest financial results and strategic updates. The announcement serves as a standard corporate disclosure ahead of the earnings release.
Transaction History
| XRAY | ▲ Buy | Grant | 556 | $0 | 10/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 432 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 43,023 | $0 | 5/30/2025 | View on chart |
| SMG | ▼ Sell | Other | 5 | $407 | 12/6/2024 | View on chart |
| SMG | ▼ Sell | Tax Withholding | 3,123 | $240K | 12/1/2024 | View on chart |
| SMG | ▲ Buy | Grant | 18,336 | $0 | 11/14/2024 | View on chart |
| SMG | ▼ Sell | Tax Withholding | 8,078 | $602K | 11/14/2024 | View on chart |
| SMG | ▼ Sell | Other | 6 | $403 | 9/6/2024 | View on chart |
| SMG | ▼ Sell | Other | 6 | $399 | 6/7/2024 | View on chart |
| SMG | ▼ Sell | Other | 6 | $395 | 3/8/2024 | View on chart |
| SMG | ▲ Buy | Grant | 10,940 | $0 | 1/23/2024 | View on chart |
| SMG | ▼ Sell | Other | 5 | $298 | 12/8/2023 | View on chart |
| SMG | ▼ Sell | Tax Withholding | 3,098 | $180K | 12/1/2023 | View on chart |
| SMG | ▼ Sell | Other | 5 | $295 | 9/8/2023 | View on chart |
| SMG | ▲ Buy | Grant | 588 | $25K | 8/15/2023 | View on chart |
| SMG | ▲ Buy | Grant | 13,580 | $0 | 12/1/2022 | View on chart |
| MTX | ▲ Buy | Open Market | 100 | $6K | 3/7/2022 | View on chart |
| MTX | ▲ Buy | Option Exercise | 2,619 | $0 | 1/26/2022 | View on chart |
| MTX | ▼ Sell | Tax Withholding | 1,337 | $94K | 1/26/2022 | View on chart |
| MTX | ▲ Buy | Option Exercise | 3,108 | $0 | 1/22/2022 | View on chart |
| MTX | ▼ Sell | Tax Withholding | 1,588 | $112K | 1/22/2022 | View on chart |
| MTX | ▲ Buy | Option Exercise | 2,848 | $0 | 1/21/2022 | View on chart |
| MTX | ▼ Sell | Tax Withholding | 1,526 | $109K | 1/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.